Looks like you’re on the UK site. Choose another location to see content specific to your location
Merck launches gene editing technology for virus-resistant CHO cell lines
Merck has announced the launch of Centinel, a new gene editing technology for use in the modification of Chinese hamster ovary (CHO) cell lines.
Centinel is designed to help engineer CHO cell lines to be resistant to minute virus of mice (MVM), a common contamination threat that remains despite the shift to chemically-defined, animal component-free biologics manufacturing processes.
The new technology targets genes that play a role in MVM susceptibility, preventing the viral contaminations that can have major consequences for biopharmaceutical manufacturers and incurring costs of hundreds of millions of dollars.
Merck has optimised the technology to provide manufacturers with an additional path for mitigating the risk of MVM contamination while maintaining an equivalent level of protein quality and cell line productivity.
Udit Batra, member of the Merck executive board and chief executive officer for life sciences, said: "The Centinel programme is just one example of how we are combining years of expertise and credibility in process development, biologics manufacturing and gene editing tools to increase safety for our customers and their patients."
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard